Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.32 |
| ▸ | SCD | O00767 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | MYC | P01106 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968132 | 0.93 | CYP2C9 (0.36) | CYP2C9KCNH2P2RX7KCNE1CCR1 | |
| SCHEMBL2957304 | 0.92 | CYP2C9 (0.39) | CYP2C9KCNH2P2RX7KCNE1CCR1 | |
| SCHEMBL2960284 | 0.82 | CYP2C9 (0.37) | CYP2C9KCNH2P2RX7KCNE1CCR1 | |
| SCHEMBL13243788 | 0.81 | CALCA (0.45) | CYP2C9KCNH2P2RX7KCNE1CCR1 | |
| SCHEMBL2970870 | 0.81 | KCNE1 (0.37) | CYP2C9KCNH2P2RX7KCNE1CCR1 | |
| SCHEMBL2968109 | 0.81 | CYP2C9 (0.37) | CYP2C9KCNH2P2RX7KCNE1CCR1 | |
| SCHEMBL2960846 | 0.81 | KCNH2 (0.41) | CYP2C9KCNH2P2RX7KCNE1CCR1 | |
| SCHEMBL2963365 | 0.79 | KCNH2 (0.51) | CYP2C9KCNH2KCNE1CCR1KCNQ1 | |
| SCHEMBL2968912 | 0.79 | KCNH2 (0.44) | CYP2C9KCNH2P2RX7KCNE1CCR1 | |
| SCHEMBL2954697 | 0.77 | KCNE1 (0.37) | CYP2C9KCNH2P2RX7KCNE1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763630-B2 | pyrimidinone compounds such as N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(tetrahydrofuran-3-yl)-1,6-dihydropyrimidine-4-carboxamide, used for treating human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | claimed |
| US-20080306051-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-11 | — | — | US | claimed |
| US-7763630-B2 | pyrimidinone compounds such as N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(tetrahydrofuran-3-yl)-1,6-dihydropyrimidine-4-carboxamide, used for treating human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763630-B2 | pyrimidinone compounds such as N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(tetrahydrofuran-3-yl)-1,6-dihydropyrimidine-4-carboxamide, used for treating human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763630-B2 | pyrimidinone compounds such as N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(tetrahydrofuran-3-yl)-1,6-dihydropyrimidine-4-carboxamide, used for treating human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| WO-2008154246-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154246-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306051-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-11 | — | — | US | disclosed |
| US-20080306051-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-11 | — | — | US | disclosed |
| US-20080306051-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306051-A1 | HIV Integrase Inhibitors | TYMP, IMPDH1, UNG | CYP2C9 655/4885KCNH2 3016/4885P2RX7 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.